Hengrui Pharmaceuticals' Xinquxibo Epirubicin Hydrochloride Tablets' new indication market application has been accepted.

Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. received a "Notice of Acceptance" from the National Medical Products Administration for its application for marketing authorization of its Haiqu BPpaethylamine tablets for the treatment of thrombocytopenia in adult patients with cancer mainly treated with chemotherapy. In May 2025, the Phase III clinical trial of the drug reached the main research endpoint, with a total of 213 patients included in the study. The results showed that the experimental group had superior efficacy and good safety. This drug had previously been approved for two indications. Currently, there is a large clinical demand in this area as treatment options are limited. As of now, the company has invested approximately 445.87 million yuan in research and development related to this project. There are uncertainties regarding the development and marketing of the drug, and the company will continue to advance the project and disclose progress.